REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Wednesday, November 6, at 4:30 p.m. ET to present its Q3 2024 financial results and recent operational highlights. The call will include a question-and-answer session for analysts, and participants are advised to join 15 minutes before the start time. A webcast replay will be available on the company's investor website approximately two hours after the call ends.
REGENXBIO (Nasdaq: RGNX) ha programmato una conferenza telefonica per mercoledì 6 novembre, alle 16:30 ET, per presentare i suoi risultati finanziari del Q3 2024 e i recenti punti salienti operativi. La chiamata includerà una sessione di domande e risposte per gli analisti, e si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario di inizio. Una registrazione in webcast sarà disponibile sul sito web per gli investitori dell'azienda circa due ore dopo la conclusione della chiamata.
REGENXBIO (Nasdaq: RGNX) ha programado una conferencia telefónica para el miércoles 6 de noviembre a las 4:30 p.m. ET para presentar sus resultados financieros del Q3 2024 y los recientes aspectos destacados operativos. La llamada incluirá una sesión de preguntas y respuestas para analistas, y se aconseja a los participantes unirse 15 minutos antes de la hora de inicio. Una repetición del webcast estará disponible en el sitio web de inversores de la compañía aproximadamente dos horas después de que finalice la llamada.
REGENXBIO (Nasdaq: RGNX)는 11월 6일 수요일 오후 4시 30분 ET에 2024년 3분기 재무 결과 및 최근 운영 주요 사항을 발표하기 위해 전화 회의를 예정하고 있습니다. 이 회의에는 분석가를 위한 질문 및 답변 세션이 포함되며, 참가자는 시작 시간 15분 전에 접속할 것을 권장합니다. 전화 회의 종료 약 2시간 후에 회사의 투자자 웹사이트에서 웹캐스트 재생이 가능합니다.
REGENXBIO (Nasdaq: RGNX) a programmé une conférence téléphonique pour le mercredi 6 novembre à 16h30 ET afin de présenter ses résultats financiers du T3 2024 et les récents points saillants opérationnels. L'appel comprendra une session de questions-réponses pour les analystes, et il est conseillé aux participants de se connecter 15 minutes avant l'heure de début. Une rediffusion du webinaire sera disponible sur le site web des investisseurs de l'entreprise environ deux heures après la fin de l'appel.
REGENXBIO (Nasdaq: RGNX) hat eine Telefonkonferenz für Mittwoch, den 6. November, um 16:30 Uhr ET angesetzt, um seine Finanzergebnisse für das 3. Quartal 2024 und die jüngsten operativen Highlights vorzustellen. Die Konferenz wird eine Frage-und-Antwort-Runde für Analysten beinhalten, und es wird empfohlen, dass Teilnehmer 15 Minuten vor Beginn der Sitzung beitreten. Eine Aufzeichnung der Webcast steht etwa zwei Stunden nach Ende der Konferenz auf der Investorenseite des Unternehmens zur Verfügung.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2024-financial-results-and-recent-operational-highlights-302291244.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) reporting Q3 2024 earnings?
How can I access REGENXBIO's (RGNX) Q3 2024 earnings call?
Will REGENXBIO's (RGNX) Q3 2024 earnings call be available for replay?
